Please use this identifier to cite or link to this item: https://doi.org/10.1002/jps.23101
Title: Designer tridentate mucin 1 aptamer for targeted drug delivery
Authors: Tan, L.
Gee Neoh, K. 
Kang, E.-T. 
Choe, W.-S.
Su, X.
Keywords: Aptamer
Cancer chemotherapy
DNA
Doxorubicin
Macrophage evasion
Oligonucleotides
Targeted drug delivery
Issue Date: May-2012
Source: Tan, L., Gee Neoh, K., Kang, E.-T., Choe, W.-S., Su, X. (2012-05). Designer tridentate mucin 1 aptamer for targeted drug delivery. Journal of Pharmaceutical Sciences 101 (5) : 1672-1677. ScholarBank@NUS Repository. https://doi.org/10.1002/jps.23101
Abstract: A single-stranded DNA aptamer (APT) capable of targeting mucin 1 (MUC1) extracellular protein was modified to increase its drug delivery specificity toward MUC1 overexpressing cancer cell line, MCF7. The active targeting region of APT was truncated and variable repeats (one, two, or three) of this sequence were synthesized. An aptamer formed from three repeats of this active targeting region (L3) was shown to possess enhanced doxorubicin (DOX) intercalation ability, and L3-DOX complex exhibited selective cytotoxicity to MCF7 over RAW cells. Most importantly, L3 was able to evade RAW 264.7 macrophages (2-fold reduction in L3 uptake relative to APT), thus resulting in an overall 5.5-fold increase of survivability of RAW cells as compared with when free DOX was used. These results indicate that aptamer L3 has good potential for targeted drug therapeutics. © 2012 Wiley Periodicals, Inc.
Source Title: Journal of Pharmaceutical Sciences
URI: http://scholarbank.nus.edu.sg/handle/10635/63708
ISSN: 00223549
DOI: 10.1002/jps.23101
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

12
checked on Dec 7, 2017

WEB OF SCIENCETM
Citations

12
checked on Nov 22, 2017

Page view(s)

32
checked on Dec 10, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.